Gene therapy startup Latus Bio has raised an additional $42 million to initiate its first clinical trials, aiming to overcome obstacles that have hindered a more advanced competitor in the field.
This year, Latus is advancing two treatments through clinical trials. The first targets a form of Batten disease known as CLN2 disease, a fatal genetic disorder characterized by seizures, vision loss, and cognitive decline. The company expects to release initial clinical data by the end of 2024.
Following this progress, Latus — founded by Beverly Davidson, chief scientific strategy officer at the Children’s Hospital of Philadelphia — is now focusing on a second drug candidate: a gene therapy for Huntington’s disease.
Related articles
Dr. Makary's Exit and the Future of Cassidy's Senate Seat: Key Health Policy Shifts
This week’s episode of “The Readout LOUD” is all about health politics. We bring on FDA reporter Lizzy Lawrence to discuss Makary’s departure — why he...
BeOne Secures FDA Approval for Novel Lymphoma Cell Therapy, Advancing Autoimmune Treatment Pipeline
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Biotech’s cell therapy boo...
Biogen’s Tau-Targeting Alzheimer’s Drug Shows Promise in Phase 2 Trial; Takeda to Cut 4,500 Jobs by 2026
Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue ski...
Biogen’s Tau-Targeting Alzheimer’s Drug Shows Promise in Mid-Stage Trial
Biogen reported mixed results Thursday from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease that targets the protein tau...
CREATE Medicines Secures $122M to Advance CAR-T Therapies for Solid Tumors and Autoimmune Diseases
CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates through human trials. Up u...
Regenxbio’s Duchenne Gene Therapy Shows Success in Trial, FDA Submission Next
Regenxbio said Thursday that its experimental gene therapy for Duchenne muscular dystrophy produced sufficiently high levels of a miniaturized muscle...
Kyle Diamantas Named Acting FDA Commissioner Amid Biotech Sector Optimism
This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their...
Gene Therapy Viruses Linked to Rare Tumor in Young Patient: FDA Commissioner Resigns Amid Safety Concerns
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Let’s get st...